Passion Capital is a partnership of entrepreneurs and operators applying their experiences to helping founders and early-stage teams build great digital media/technology companies. They are Stefan Glaenzer, Eileen Burbidge and Robert Dighero.  They have been personally involved in the largest European technology exits of the past decade, including the biggest exits of the year for 4 of the past 10 years by market value (Ricardo.de acquired by QXL, Skype purchased by Ebay, Last.fm acquired by CBS, and QXL/Tradus acquired by Naspers) and want to be involved in many more.  They believe that the critical differentiator and key asset of a successful business is the passion and ability of its founders.  They are committed to fostering an ecosystem of technology, collaboration and executional excellence in Europe. As an example of this, White Bear Yard is their own hub for activities, ambitions and energy and where have fun in the process.

Passion Capital

PDS Ventures is the venture arm of PDS Multinational.

PDS Ventures

Speedinvest is one of Europe’s most active early-stage investors, with more than €1bn AUM, 40 investors, and offices in Berlin, London, Munich, Paris, Vienna and San Francisco.  Your success is our priority, so we don’t just send some money and ''check in'' at board meetings. Our mission is to empower you with game-changing support through every stage of your journey.  Our focused investment teams know your industry inside and out. Their Deep Tech, Fintech, Industrial Tech, Network Effects, Digital Health and Subscriptions experience, know-how and deep networks are yours from day one.  You also have full access to our in-house Platform+ team of operational experts who can provide tailored growth marketing, people (HR), US business development, and networking support throughout every stage of your journey.

Speedinvest

Notion is an entrepreneur-led venture capital firm that focuses on high potential businesses in the Cloud Computing and Software-as-a-Service (SaaS) markets. It is an early-stage venture fund that focuses mainly on technology and cloud computing markets. The firm helps European tech companies fulfill their potential and achieve a massive scale. Notion invests early when it can build strong relationships and help to shape the future success of its companies. Notion Capital was founded in 2009 and is headquartered in London, England.

Notion Capital

Triple Point Ventures is an early stage VC based in London, investing in promising start-ups across multiple sectors including ecommerce, AI, platforms and wider tech. TP's team offers entrepreneurs something a bit different - a fusion of funding and operational expertise, helping investee companies fulfil their growth plans at speed while ensuring teams themselves reach their full potential as they expand.   Triple Point has funded many companies, including Skin Analytics, LendInvest, Contis Group, Capital on Tap, Payment Sense, Flatfair and MWS Technology. Several TP-backed companies have featured in start-up charts such as The Sunday Times Tech Track 100. TP recently began raising its second £30 million venture fund to invest in early stage companies who are addressing identified challenges in the B2B or B2B2C world. Triple Point Ventures is the venture capital arm of the wider Triple Point Investment Management group. The Triple Point Group manages over £1.5 billion in assets across multiple strategies including debt, infrastructure, real estate and venture capital. The group was established in 2004 as a UK venture capital trust manager and has continued to provide strong risk-adjusted returns to investors throughout this time.

Triple Point Ventures

Tiny VC

Conviction is a syndicate of global investors pursuing early stage, SaaS based disruptive tech opportunities. Conviction invests exclusively in post-revenue businesses that are disrupting their domestic markets and show the potential to grow into global enterprises with $100m revenue lines.   The Conviction partnership is led by founding shareholder Andrew Jenkins, who has invested in disruptive technologies for 10 years, most notably Mimecast, which is now Nasdaq listed at over $2bn.    Andrew is supported by Jeremy Middleton CBE, Managing Director of successful private investment company Middleton Enterprises Limited, and co-founder of home emergencies repairs business HomeServe plc, now a FTSE 250 company valued at over £2.5bn.

Conviction VC

Calm/Storm Ventures is a founder network and boutique venture capital firm that invests in solutions improving health and wellbeing. They invest in founders that change lives for the better. Calm/Storm Ventures believe in lifelong learning and personal growth, empowering entrepreneurs with unique access to successful founders.

Calm/Storm Ventures

EQT, a purpose-driven global investment organization with a Nordic heritage, the foundation exists to push the frontiers of impact.

EQt Foundation

Fertifa

Fertifa is an innovative employer benefit solution making fertility care more accessible and affordable. The company works with employers to offer a valuable employee benefit which bridges the gap between an employer and their employees when dealing with the sensitivity and privacy of employees’ reproductive issues. It also offers guidance and advice, next-generation fertility treatment, and access to a range of holistic services for the best chance of success.  The company was founded in 2019 and based in London, United Kingdom.

Fertifa is a UK based digital fertility employee benefits startup. It offers a digital fertility clinic for employees where it allows individuals to consult specialists in person or online, communicate with fertility advisors, purchase at-home fertility testing kits and access Fertifa’s educational material. It also offers data analytics and corporate administration for employers.

Long-term demographic changes are finally bringing fertility technologies into focus.

Fertility Tech

Fertifa enables companies to offer fertility and reproductive health benefits

Fertifa is a UK based digital fertility employee benefits startup. It offers a digital fertility clinic for employees where it allows individuals to consult specialists in person or online, communicate with fertility advisors, purchase at-home fertility testing kits and access Fertifa’s educational material. It also offers data analytics and corporate administration for employers.In November 2020, the company raised GBP 1 million (approximately USD 1.3 million) in seed funding, which it intends to invest in growing its customer base which currently consists of 700,000 UK employees, and expand its presence across the UK and Europe by improving its product offering.

<div>
 
 Glow offers apps that track data related to women’s fertility including ovulation cycle and pregnancy tracking. In addition to apps, the company also offers individualized fertility coaching, clinic identification and community support, and links patients with clinics for procedures such as egg freezing. 
 
 
 Glow generated around USD 0.3 million monthly revenue in October 2020, and as of February 2019 it had around 15 million users, and claims to have helped about 950,000 women get pregnant (from May 2013 to February 2019). In February 2019 Glow partnered with US Match Group (provider of dating products such as Match.com and Tinder), to provide Match’s employees with egg freezing benefits at reputed fertility clinics. In May 2017 it partnered with the National Institute of Health (NIH) to update a prediction model for couples trying to conceive.  
 
 
 In 2020, the company faced investigations into privacy and security failures involving its app. Glow agreed to pay a USD 0.25 million settlement in September 2020.
 
 
 
</div>

Glow

<div>
 
 Inne, based in Germany, offers an at-home mini lab kit for women. Hormone analysis is conducted based on saliva samples. The lab device connects to smartphones for storage and access to the analysis results.
 
 
 Unlike peer offerings, Inne does not attempt to predict future cycles and fertility dates, and instead educates users about their bodies, with information on what changes they should feel in response to the hormonal levels on the day.
 
 
 In May 2022, Inne 
 <a href="https://sp-edge.com/updates/10667?industryIds=40">
 raised USD 10 million
 </a>
 in an extension to its Series A round led by DSM Venturing. The company utilized the funds to continue the development of its mini lab and platform, grow its team, and support its expansion across the US, where it aims to enter with its perimenopause feature, followed by an expanded product launch in late 2022.
 
 
 
</div>

Inne

Proov (formerly known as MFB Fertility) offers the at-home “Proov'' ovulation and progesterone test. Proov tracks hormone levels in urine over multiple days, after suspected ovulation, and estimates whether the progesterone levels are sufficient for implantation, during the 7-10 day implantation window.As of May 2021, it was the only FDA-cleared urine PdG (urine metabolite of the progesterone hormone) test, and its method of determining the fertile window was patented. Moreover, it received the CE marking and expanded its sales footprint to Europe in June 2021.In June 2020, the company received a USD 1.3 million deal from the US Air Force, to provide Proov kits to enrolled individuals. The Proov test was distributed through leading US retailers such as Target and Amazon, and was also used by doctors across the country.Proov raised USD 9.7 million in Series A funding in December 2021, in a round led by Hambrecht Ducera Growth Ventures, with participation from other venture capital firms such as SteelSky Ventures, WCC Partners, and Lightship Capital, among others. The company expects to use the funding to grow its “Complete” product, which includes follicle-stimulating hormone tests and other multi-hormone tests that measure estrone glucuronide, LH and PdG.

Proov

<div>
 
 Progyny works with employers (primarily large enterprises in the US) to optimize the fertility benefits they offer for their employees. It connects employees to fertility specialists and clinics, and also offers extensive support to patients through their Progyny Patient Care Advocates, who provide clinical guidance, education, and emotional support.
 
 
 The company was founded as a fertility education platform and eventually included in vitro fertilization (IVF) referral network Fertility Authority and reproductive health company Auxogyn, into its network. The company pivoted into offering fertility benefit solutions in 2016, and launched Progyny Rx (fertility medication benefit) in 2018.
 
 
 Progyny connects patients to a network of 800 fertility specialists and nearly 600 clinic locations.&nbsp;
 
 
 Key customers and partnerships
 
 
 As of March 2022, the company served 264 enterprise customers (including Facebook, Microsoft, Google, and Nasdaq), and had 3.9 million active members.
 
 
 Funding and financials
 
 
 In October 2019, Progyny raised USD 130 million through its IPO, where it was listed on the Nasdaq.
 
 
 In FY2021, the company reported a revenue of USD 500.6 million reflecting a 45% YoY growth and a net income of USD 65.8 million. The company&rsquo;s revenue for 
 <a href="https://sp-edge.com/updates/14396">
 Q3 FY2022
 </a>
 amounted to USD 205.4 million, representing 68% YoY growth. The management&rsquo;s revenue guidance for FY2022 ranges between USD 775 million and USD 785 million, which implies an YoY growth of 55% to 57%.
 
</div>

Progyny

<div>
 
 Prima Temp offers the artificial intelligence (AI) assisted “Priya” intarvaginal ring sensor and accompanying app to continuously measure a woman’s core body temperature, predicting fertility windows. The app uses big data to improve its predictions, and the app notifies the user of fertile windows. The company also offers the “Kindara” fertility tracking app, which provides fertility related education and links users to a community of over 140,000 members.  
 
 
 The company raised USD 5 million in funding in May 2019 from Gedeon Richter, a Hungarian pharmaceutical company. Although the company primarily focuses on fertility monitoring, it intends to expand its offerings to include other areas of fertility management such as contraception and menopause.  
 
 
 
 
 
</div>

Prima Temp

Test kits which use saliva, blood, or temperature to determine hormone levels and form conclusions on fertility and fertility cycles.


Apps which use data science to identify fertility windows.

Organizations that freeze eggs or embryos for usage at a future date.


Services that analyze sperm samples (via test kit) and/or offer storage facilities for future use.

Companies specializing in supporting patient decision making, financing, clinical visits, physician referrals, and at-home treatments

Offers digital platforms and apps to provide fertility-related support

Uses AI/ML to improve cycle predictions and track symptoms

Some startups use genetic screening to tailor treatment or identify underlying issues

Fertifa

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless